𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Posters display III clinical outcome and PET

✍ Scribed by N. Nestor Perez Baliño; O. Masoli; S. Traverso; L. Grynberg; C. Rappallo; M. Redruello; D. Rosa; D. Cragnolino; A. Meretta; L. Vidal


Publisher
Springer
Year
2005
Tongue
English
Weight
255 KB
Volume
12
Category
Article
ISSN
1071-3581

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Humoral response to catumaxomab correlat
✍ Marion G. Ott; Frederik Marmé; Gerhard Moldenhauer; Horst Lindhofer; Michael Hen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 893 KB

The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (__n__ = 258) with malignant ascites, catumaxomab showed a clear clinical benefit __vs__. paracentesis and had an acceptable safety pr

Clinical outcomes of the KYOCERA Physio
✍ Akihiko Matsumine; Takafumi Ueda; Takashi Sugita; Yasuo Yazawa; Kazuo Isu; Akira 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

## Abstract ## Background and Objectives The KYOCERA Physio Hinge Total Knee System Type III (PHKIII) was developed to reconstruct bony defects of the distal femur. The PHKIII is originative in that the metallic parts are fully made of titanium alloy, and this prosthesis has a unique semi‐rotating